Alimera Sciences, Inc. announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Approvals in Finland and Luxembourg mark the 14th and 15th European approvals through the Repeat-Use application procedure. ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom, Germany and Portugal.

The company expects to begin commercializing ILUVIEN in the U.S. in February 2015. ILUVIEN is pending approval in the Czech Republic and Poland, the two remaining countries in the European Union (EU) included in the Repeat-Use application procedure.